View Older Stories View More Recent Stories

Apr 29, 2022 10:04AM Mesoblast Limited (MESO) PT Lowered to $12 at Dawson James, "Focus Remains on BLA Filing for remestemcel-L"
Apr 29, 2022 07:53AM BMO Capital Reiterates Outperform Rating on Bristol-Myers Squibb Co. (BMY)
Apr 29, 2022 06:42AM DexCom (DXCM) PT Lowered to $520 at Stifel Following Q1 Report, but "Buy" Rating Maintained, "Bulk of The Headwinds are Transient in Nature"
Apr 29, 2022 06:40AM Cytokinetics (CYTK) PT Raised to $75 at H.C. Wainwright, "Aficamten Is Next and Could Do Better" than BMY's Recently Approved Camzyos
Apr 28, 2022 05:25PM Cantor Fitzgerald Reiterates Overweight Rating, $21 Price Target on SeaSpine Holdings (SPNE)
Apr 28, 2022 05:13PM BMO Capital Reiterates Market Perform Rating, $64 Price Target on Gilead Sciences (GILD) Following Q1 Report, "Continue to See Gilead at a Crossroads"
Apr 28, 2022 07:49AM "Expect LLY Shares to Trade Higher" on tirzepatide and Q1 Results - Mizuho Securities Reiterates Buy Rating, $315 Price Target on Eli Lilly (LLY)
Apr 28, 2022 07:47AM BioMarin Pharmaceutical (BMRN) PT Lowered to $94 at Oppenheimer, Analysts Awaits "Better Conviction on Potential Stock Drivers"
Apr 28, 2022 07:44AM BMO Capital Reiterates Outperform Rating, $330 Price Target on Eli Lilly (LLY) on Earnings, Highlights "Strong Obesity Data"
Apr 28, 2022 07:43AM "Company Has a Promising Growth Profile" - Raymond James Reiterates Outperform Rating on BioMarin Pharmaceutical (BMRN)
Apr 28, 2022 06:19AM Truist Securities Reiterates Buy Rating on Viking (VKTX) on Q1 Report, "We Like Risk/Reward Here"
Apr 27, 2022 05:15PM BMO Capital Reiterates Market Perform Rating, $263 Price Target on Amgen (AMGN) Following Q1 Report, "Still See Pricing Headwinds Impacting Core Franchises"
Apr 27, 2022 10:46AM Alkermes (ALKS) PT Raised to $27 at Stifel on Q1 Beat, Strong Lybalvi Launch
Apr 27, 2022 09:46AM Cantor Fitzgerald Reiterates Overweight Rating, $12 Price Target on Lucid Diagnostics Inc (LUCD) on BeiGene's RATIONALE 306 Trial Data, "Encourage Investors to Acquire LUCD Shares at an Attractive Ent
Apr 27, 2022 08:39AM Recent Capital Raise "Does Not Eliminate the Company’s Financing Risk" - Dawson James Keeps Arcimoto (FUV) at Neutral Rating
Apr 27, 2022 07:59AM Mizuho Securities Reiterates Buy Rating, $35 Price Target on Alkermes (ALKS)
Apr 27, 2022 05:58AM KRTX "Remains One of Top SMID Cap Picks" on KarXT's Potential, Model 75% Probability of Success - Karuna Therapeutics (KRTX) PT Hiked to $190 at Mizuho Securities\
Apr 27, 2022 05:55AM Veru (VERU) and Opiant (OPNT) Top Cantor Fitzgerald's List of Largest Short Interest Increases
Apr 26, 2022 02:18PM Needham & Company Reiterates Buy Rating, $12 Price Target on Gamida Cell (GMDA)
Apr 26, 2022 09:54AM Stifel Reiterates Buy Rating on Fate Therapeutics (FATE)
Apr 26, 2022 09:46AM Dawson James Reiterates Buy Rating. $10 Price Target on Citius Pharmaceuticals (CTXR)
Apr 26, 2022 08:51AM Cantor Fitzgerald Reiterates Overweight Rating, $7 Price Target on VolitionRX (VNRX)
Apr 26, 2022 06:29AM UroGen Pharma (URGN) PT Lowered to $21 at Oppenheimer on Slower Jelmyto Launch, Reiterates Outperform Rating, Sees Situation Improving in 2022 and Beyond
Apr 26, 2022 06:15AM Oppenheimer Reiterates Outperform Rating, $8 Price Target on Mustang Bio (MBIO), Continues to "View MB-106 as an Attractive Potential Alternative to Currently Approved CD19 CAR-T Products"
Apr 26, 2022 05:59AM Raymond James Reiterates Outperform Rating, $24 Price Target on G1 Therapeutics (GTHX) Following Latest IQVIA Sales Data
Apr 26, 2022 05:57AM Neurocrine (NBIX) Earnings Preview: Mizuho Models Sales of $288.2M, Seeks Clarity on Post-COVID Recovery, Reiterates Neutral Rating with $95 Price Target
Apr 26, 2022 05:54AM Acadia Pharmaceuticals (ACAD) Earnings Preview: Mizuho Sees Q1 Nuplazid Sales of $120M, Hopes to Hear Updates on Review of Nuplazid for Alzheimer's, Reiterates Neutral Rating
Apr 26, 2022 05:31AM Stifel Reiterates Hold Rating on Nektar Therapeutics (NKTR) on Cost Restructuring, Sees NKTR-358 as "Growth Driver Going Forward"
Apr 26, 2022 05:29AM Mizuho Securities Maintains Nektar Therapeutics (NKTR) at Neutral Rating with $6 Price Target on Cost Restructuring, But Pipeline Remains a Concern
Apr 25, 2022 09:20AM Stifel Reiterates Buy Rating, $10 Price Target on Cerus (CERS) on ARC Deal, Sees it as "Robust Commitment" to INTERCEPT Platform
Apr 25, 2022 07:38AM UPDATE: Eliem Therapeutics (ELYM) Reiterated at Buy by Stifel Despite ETX-810 Failure, "Still Like LSR Set-Up, But Stock Now Materially Riskier"
Apr 22, 2022 06:20AM Mizuho Securities Reiterates Buy Rating, $35 Price Target on Alkermes (ALKS) Ahead of Earnings, Sees "Lybalvi Launch" as Key Area of Investor Focus
Apr 22, 2022 06:18AM SeaSpine Holdings (SPNE) PT Lowered to $21 at Cantor Fitzgerald on Lower Guidance, but Analyst Reiterates "Overweight", Encourages "Investors to Acquire SPNE's Shares at Attractive Valuation"
Apr 22, 2022 06:14AM Stifel Reiterates Hold Rating, $70 Price Target on Globus Medical (GMED) Despite "Surprising CEO Resignation"
Apr 21, 2022 09:11AM Bluejay Diagnostics (BJDX) PT Lowered to $8 at Dawson James on Dilution, Reiterates "Buy" Rating, Sees 30% Chance of Success of Symphony
Apr 20, 2022 09:08AM Dawson James Reiterates Buy Rating, $3 Price Target on Dare Bioscience (DARE)
Apr 20, 2022 05:54AM Expert Believes "The Trial Will Hit its Primary Efficacy Endpoint" - Raymond James Bullish on argenx SE (ARGX) Ahead of efgartigimod Phase 3 Readout
Apr 19, 2022 05:10PM Stifel Reiterates Buy Rating, $36 Price Target on Athira Pharma (ATHA) Ahead of ATH-1017 Readout
Apr 19, 2022 09:34AM Truist Securities Reiterates Buy Rating, $125 Price Target on BioXcel Therapeutics (BTAI) on $260M Financing, Sees it Removing Cash Overhang
Apr 19, 2022 08:48AM BMO Capital Reiterates Outperform Rating, $780 Price Target on Regeneron Pharma (REGN) Following Checkmate (CMPI) Acquisition
Apr 19, 2022 08:21AM "We Remain Optimistic on FDA Approving AXS-005 in Coming Weeks" - Mizuho Securities Reiterates Axsome Therapeutics (AXSM) at Buy with $51 Price Target
Apr 19, 2022 07:58AM Regeneron's (REGN) Acquisition of Checkmate (CMPI) Supports Thesis of "Uptick in M&A" in SMID-cap Biotechs - Truist Securities
Apr 19, 2022 07:07AM Acadia Pharmaceuticals (ACAD) PT Lowered to $27 at Mizuho Securities on ACP-044 Failure, Expects "Modest Weakness" in Shares
Apr 19, 2022 06:58AM Needham & Company Reiterates Hold Rating on Acadia Pharmaceuticals (ACAD) on ACP-044 Failure, Sees Minimal Impact, "Wouldn't Be Surprised if the Stock Bounces"
Apr 18, 2022 09:56AM Dawson James Reiterates Buy Rating, $10 Price Target on Citius Pharmaceuticals (CTXR)
Apr 18, 2022 09:45AM Needham & Company Reiterates Buy Rating, $7 Price Target on Selecta Biosciences (SELB)
Apr 18, 2022 08:54AM Needham & Company Reiterates Buy Rating, $13 Price Target on Autolus Therapeutics (AUTL)
Apr 18, 2022 08:11AM Brookline Capital Markets Reiterates Buy Rating. $12 Price Target on CTI BioPharma (CTIC), Notes Recent NCCN Announcement "Support Our Outlook"
Apr 18, 2022 06:14AM Cowen Reiterates Outperform Rating, $75 Price Target on Gilead Sciences (GILD), Sees Potential for "Very Significant Upside to GILD Shares"
Apr 14, 2022 04:59PM Magenta Therapeutics (MGTA) PT Lowered to $8 at Mizuho Securities, but Analyst Maintains Buy Rating, Continues to See Upside from Current Valuation
View More Recent Stories View Older Stories